IGHG3 and COVID-19: From enrollment to 1 MPE, anti-S IgG1 and IgG3 levels significantly increased among all hospitalized patients, whereas anti-S IgG2 and IgG4 only increased over time among patients with moderate disease or those who died from COVID-19.